Precisely Announces EngageOne RapidCX, Revolutionizing Customer Communications Management for Highly Regulated Industries
17.5.2023 16:30:00 EEST | Business Wire | Press release
Precisely, the global leader in data integrity, today announced the launch of EngageOne RapidCX, bringing the latest innovation in customer communications management (CCM) to the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005070/en/
Precisely, the global leader in data integrity, announces the launch of EngageOne RapidCX, bringing the latest innovation in customer communications management (CCM) to the market. (Photo: Business Wire)
RapidCX empowers organizations to provide a better, more effective customer experience through data-driven, personalized, communications. This is particularly important for highly regulated industries such as financial services, insurance, and telecommunications, where the pressure is on to deliver more personalized and dynamic customer experiences to stay competitive, while also navigating increasingly complicated regulatory requirements.
Announced at the Trust ‘23 Data Integrity Summit, RapidCX allows organizations to solve challenges such as disjointed customer communications, compliance with changing regulations, and siloed legacy systems to:
- Improve Efficiencies – replace manual customer experience processes with an automated solution that enables business users to harness data from across all systems.
- Enhance Customer Engagement – capture data-driven insights to quickly and easily personalize and automate omnichannel communications, including e-mails, SMS messages, chatbot conversations, interactive video and more.
- Enable Better Governance – ensure compliance with end-to-end communications tracking, delivery tracing, and archiving. Easy-to-manage governance controls make even complicated industry regulations easier to follow.
“The launch of RapidCX is a significant industry event and a real game changer for Precisely, particularly in highly regulated markets,“ said Kaspar Roos, Founder & CEO at Aspire. “Precisely has brought together a wide variety of standalone capabilities into a comprehensive, fully managed cloud-based platform, providing a simplified way for customers to get access to modern customer-focused technologies without the need for extensive integration. The launch positions Precisely favorably to meet the needs of a new generation of CCM buyers found in marketing, customer experience, and the line-of-business.”
The announcement of the new platform is well-timed, with customer loyalty being harder to come by in recent years due to shifts in consumer behavior, rising competition, and economic pressures. In fact, a recent PwC survey showed that more than half of consumers (55%) would stop buying from a company, even if they otherwise liked them, after having several bad experiences – with a further 8% saying they would stop after just one negative experience.
With the rollout of RapidCX, organizations worldwide can now easily and dynamically deliver satisfying, personalized experiences, no matter how, where or when the customer chooses to interact. When combined with the Precisely portfolio of data integrity solutions, organizations can ensure they are powering customer communications delivery with trusted data, helping to win lasting loyalty and, ultimately, accelerate business growth.
“Businesses can no longer apply a one-size-fits-all approach to customer engagement. Today's customers expect extraordinary experiences, and trusted data is the cornerstone for delivering them,” said Greg Van den Heuvel, Executive Vice President and General Manager – Engage Solutions at Precisely. “Forward-thinking organizations are turning to cloud hosted integrated customer engagement platforms, fueled with accurate, consistent, and contextual data, to revolutionize their approach to customer communications.”
Learn more about RapidCX here.
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005070/en/
Contact information
Press
Emma Forrest (Global)
press@precisely.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
